{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:35:10Z","timestamp":1784043310068,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2022.02.070","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T16:44:03Z","timestamp":1647017043000},"page":"2299-2310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9960-2279","authenticated-orcid":false,"given":"Hong-Jyun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-3478","authenticated-orcid":false,"given":"Chih-Peng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-6679","authenticated-orcid":false,"given":"Tzong-Shiann","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-853X","authenticated-orcid":false,"given":"Yu-San","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen-Mao","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-3080","authenticated-orcid":false,"given":"Yen-Chung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Peng","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Hsuan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trai-Ming","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Shin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-7992","authenticated-orcid":false,"given":"Shu-Wen","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.070_b0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"Dengue. Lancet."},{"key":"10.1016\/j.vaccine.2022.02.070_b0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.02.070_b0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular insight into dengue virus pathogenesis and its implications for disease control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.02.070_b0020","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(16)30473-X","article-title":"Dengue: knowledge gaps, unmet needs, and research priorities","volume":"17","author":"Katzelnick","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0025","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1016\/j.vaccine.2013.06.079","article-title":"Identifying protective dengue vaccines: guide to mastering an empirical process","volume":"31","author":"Halstead","year":"2013","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.02.070_b0030","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1016\/j.vaccine.2017.08.066","article-title":"Live-attenuated tetravalent dengue vaccines: the needs and challenges of post-licensure evaluation of vaccine safety and effectiveness","volume":"35","author":"Wichmann","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.02.070_b0035","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1126\/science.358.6370.1514","article-title":"Safety concerns derail dengue vaccination program","volume":"358","author":"Normile","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.02.070_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2022.02.070_b0045","article-title":"Is Dengvaxia a useful vaccine for dengue endemic areas?","volume":"367","author":"Gubler","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.02.070_b0050","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0055","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fimmu.2020.01055","article-title":"Challenges in dengue vaccines development: pre-existing infections and cross-reactivity","volume":"11","author":"Izmirly","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2022.02.070_b0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","article-title":"Domain III of the envelope protein as a dengue vaccine target","volume":"9","author":"Guzman","year":"2010","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2022.02.070_b0070","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","volume":"385","author":"Guzman","year":"2015","journal-title":"Dengue. Lancet."},{"key":"10.1016\/j.vaccine.2022.02.070_b0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.micinf.2008.12.004","article-title":"A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity","volume":"11","author":"Leng","year":"2009","journal-title":"Microbes Infect."},{"key":"10.1016\/j.vaccine.2022.02.070_b0080","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00705-013-1639-1","article-title":"A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates","volume":"158","author":"Chen","year":"2013","journal-title":"Arch Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0085","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/JVI.73.7.6104-6110.1999","article-title":"Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion","volume":"73","author":"Flamand","year":"1999","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.antiviral.2013.03.008","article-title":"The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker","volume":"98","author":"Muller","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.vaccine.2022.02.070_b0095","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/343813","article-title":"High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever","volume":"186","author":"Libraty","year":"2002","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/imm.12748","article-title":"Pathogenesis of vascular leak in dengue virus infection","volume":"151","author":"Malavige","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2022.02.070_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","author":"Beatty","year":"20157304141","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.vaccine.2022.02.070_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity","author":"Modhiran","year":"20157304142","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.vaccine.2022.02.070_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005738","article-title":"Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability","volume":"12","author":"Puerta-Guardo","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2022.02.070_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007033","article-title":"Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability","volume":"14","author":"Chen","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2022.02.070_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004828","article-title":"Dengue virus nonstructural protein 1 induces vascular leakage through macrophage migration inhibitory factor and autophagy","volume":"10","author":"Chen","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007625","article-title":"Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage","volume":"15","author":"Chao","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2022.02.070_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005053","article-title":"Activation of TLR2 and TLR6 by dengue NS1 protein and its implications in the immunopathogenesis of dengue virus infection","volume":"11","author":"Chen","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2022.02.070_b0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/1096-9071(20000201)63:2<143::AID-JMV1009>3.0.CO;2-L","article-title":"Generation of IgM anti-platelet autoantibody in dengue patients","volume":"63","author":"Lin","year":"2001","journal-title":"J Med Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jmv.10261","article-title":"Antibodies from dengue patient sera cross-react with endothelial cells and induce damage","volume":"69","author":"Lin","year":"2003","journal-title":"J Med Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.174.1.395","article-title":"Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1","volume":"174","author":"Lin","year":"2005","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0155","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4049\/jimmunol.1201976","article-title":"Anti-dengue virus nonstructural protein 1 antibodies cause NO-mediated endothelial cell apoptosis via ceramide-regulated glycogen synthase kinase-3\u03b2 and NF-\u03baB activation","volume":"191","author":"Chen","year":"2013","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3181\/0805-RM-147","article-title":"Proteomic analysis of endothelial cell autoantigens recognized by anti-dengue virus nonstructural protein 1 antibodies","volume":"234","author":"Cheng","year":"2009","journal-title":"Exp Biol Med (Maywood)."},{"key":"10.1016\/j.vaccine.2022.02.070_b0165","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.0800672","article-title":"Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency","volume":"183","author":"Chen","year":"2009","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092495","article-title":"Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1","volume":"9","author":"Wan","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.02.070_b0175","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.1601523","article-title":"Therapeutic effects of monoclonal antibody against dengue virus NS1 in a STAT1 knockout mouse model of dengue infection","volume":"199","author":"Wan","year":"2017","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12929-018-0462-0","article-title":"Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate","volume":"25","author":"Chen","year":"2018","journal-title":"J Biomed Sci."},{"key":"10.1016\/j.vaccine.2022.02.070_b0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-virology-101416-041848","article-title":"The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis","volume":"5","author":"Glasner","year":"2018","journal-title":"Annu Rev Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/vaccines9060622","article-title":"Flavivirus NS1 and its potential in vaccine development","volume":"9","author":"Carpio","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.vaccine.2022.02.070_b0195","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.vaccine.2022.02.070_b0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody","volume":"392","author":"Wahala","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.02.070_b0205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2007.05.042","article-title":"Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus","volume":"366","author":"Gromowski","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.02.070_b0210","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1128\/JVI.01087-10","article-title":"Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2","volume":"84","author":"Sukupolvi-Petty","year":"2010","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","article-title":"The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry","volume":"9","author":"Chin","year":"2007","journal-title":"Microbes Infect."},{"key":"10.1016\/j.vaccine.2022.02.070_b0220","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.02.070_b0225","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/j.vaccine.2010.10.004","article-title":"A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice","volume":"28","author":"Block","year":"2010","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.02.070_b0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jinf.2011.11.023","article-title":"Dengue virus nonstructural protein NS1 binds to prothrombin\/thrombin and inhibits prothrombin activation","volume":"64","author":"Lin","year":"2012","journal-title":"J Infect."},{"key":"10.1016\/j.vaccine.2022.02.070_b0235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.abb9425","article-title":"A broadly protective antibody that targets the flavivirus NS1 protein","volume":"371","author":"Modhiran","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.02.070_b0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1126\/science.abc0476","article-title":"Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction","volume":"371","author":"Biering","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.02.070_b0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3844\/ajidsp.2008.85.91","article-title":"C-terminal region of dengue virus nonstructural protein 1 is involved in endothelial cell cross-reactivity via molecular mimicry","volume":"4","author":"Wan","year":"2008","journal-title":"Am J Infect Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0250","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/14760584.2016.1116948","article-title":"T cell immunity to dengue virus and implications for vaccine design","volume":"15","author":"Rivino","year":"2016","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2022.02.070_b0255","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.4049\/jimmunol.1900136","article-title":"Combination of modified NS1 and NS3 as a novel vaccine strategy against dengue virus infection","volume":"203","author":"Kao","year":"2019","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0260","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/fmb.13.171","article-title":"Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections","volume":"9","author":"Mathew","year":"2014","journal-title":"Future Microbiol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0265","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.4049\/jimmunol.1401597","article-title":"CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice","volume":"193","author":"Zellweger","year":"2014","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2022.02.070_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004277","article-title":"Cooperation between CD4+ T cells and humoral immunity is critical for protection against dengue using a DNA vaccine based on the NS1 antigen","volume":"9","author":"Gon\u00e7alves","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.vaccine.2022.02.070_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163240","article-title":"Aspects of T cell-mediated immunity induced in mice by a DNA vaccine based on the dengue-NS1 antigen after challenge by the intracerebral route","volume":"11","author":"Oliveira","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.02.070_b0280","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2022.02.070_b0285","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191548","article-title":"Relative contribution of nonstructural protein 1 in dengue pathogenesis","volume":"217","author":"Lee","year":"2020","journal-title":"J Exp Med."},{"key":"10.1016\/j.vaccine.2022.02.070_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007721","article-title":"Detection of post-vaccination enhanced dengue virus infection in macaques: an improved model for early assessment of dengue vaccines","volume":"15","author":"Borges","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2022.02.070_b0295","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1473-3099(18)30126-9","article-title":"The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy","volume":"18","author":"Anderson","year":"2018","journal-title":"Lancet Infect Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:57Z","timestamp":1759403517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":59,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X22002250"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}